Health Care • Biotechnology: Commercial Physical & Biological Resarch
$215.48 ▲ +1.32
(+0.62%)
MKT CAP: $16.50B • VOL: 1.80M
52W L $67 52W H $219
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$181
MEDIAN
$241
MEAN
$246
HIGH
$293
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ICLR TAPE
ICLR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $260.73 | $247.80 | 2025-02-14 | $196.09 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $271.50 | $254.27 | 2025-02-06 | $202.55 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $245.65 | $237.03 | 2025-01-29 | $206.86 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $219.79 | — | 2025-01-17 | $211.17 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $189.62 | $204.71 | 2025-01-09 | $191.78 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $256.42 | $224.10 | 2024-12-18 | $187.47 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $209.02 | $217.63 | 2024-12-04 | $200.40 | -4.3% | 48% | C |